#Karyopharm hashtag - Bluesky

@pharmaphorum.bsky.social

2 weeks ago

Karyopharm eyes Xpovio filing in myelofibrosis on mixed data Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis

Despite hitting just one of two efficacy endpoints in a pivotal trial, #Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.

pharmaphorum.com/news/karyoph...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Karyopharm Therapeutics Secures $30 Million in Private Placement for Innovative Cancer Therapies Karyopharm Therapeutics has announced a $30 million private placement with RA Capital Management to bolster its oncology pipeline, potentially increasing funding with warrant exercises.

Karyopharm Therapeutics Secures $30 Million in Private Placement for Innovative Cancer Therapies #USA #Karyopharm #XPOVIO #Newton #RA_Capital

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Karyopharm Therapeutics Announces New Employee Inducement Grants Under Nasdaq Rules Karyopharm Therapeutics has announced the granting of restricted stock units to new hires, enhancing its commitment to attracting top talent in the oncology field.

Karyopharm Therapeutics Announces New Employee Inducement Grants Under Nasdaq Rules #USA #Karyopharm #XPOVIO #Newton #KPTI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Karyopharm Therapeutics Announces 2025 Financial Results and Key Milestones Ahead Karyopharm Therapeutics has shared its financial results for 2025, highlighting growth, product performance, and key upcoming trials set for 2026.

Karyopharm Therapeutics Announces 2025 Financial Results and Key Milestones Ahead #United_States #Karyopharm #XPOVIO #Newton #Therapeutics

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Karyopharm Therapeutics Grants Restricted Stock Units to New Hires Under Nasdaq Rules Karyopharm Therapeutics has announced the grant of restricted stock units to four new employees. The grant aligns with Nasdaq Listing Rule 5635(c)(4).

Karyopharm Therapeutics Grants Restricted Stock Units to New Hires Under Nasdaq Rules #USA #Karyopharm #XPOVIO #Newton #KPTI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Karyopharm Projects Significant Revenue Gains and Anticipates Transformative Clinical Data in 2026 Karyopharm Therapeutics has announced preliminary revenue figures and emphasizes their goals for transformative clinical data in 2026. Key trials are on track!

Karyopharm Projects Significant Revenue Gains and Anticipates Transformative Clinical Data in 2026 #United_States #cancer_therapy #Karyopharm #XPOVIO #Newton

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Karyopharm Therapeutics to Join Baird's Biotech Discovery Series Event Karyopharm Therapeutics is set to participate in the Baird Biotech Discovery Series, featuring insights from expert Dr. Claire Harrison.

Karyopharm Therapeutics to Join Baird's Biotech Discovery Series Event #Cancer_Research #Karyopharm #XPOVIO

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Karyopharm Therapeutics to Participate in Piper Sandler's Annual Healthcare Conference Karyopharm Therapeutics is set to engage in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, in New York.

Karyopharm Therapeutics to Participate in Piper Sandler's Annual Healthcare Conference #United_States #New_York #healthcare #Karyopharm #XPOVIO

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Karyopharm's Third Quarter 2025 Financial Report Reveals Company Advancements in Cancer Treatment Trials Karyopharm Therapeutics reveals positive financial growth and major clinical developments in its cancer therapies, especially XPOVIO, for Q3 2025.

Karyopharm's Third Quarter 2025 Financial Report Reveals Company Advancements in Cancer Treatment Trials #United_States #Karyopharm #XPOVIO #Newton #Myelofibrosis

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Karyopharm Secures $100 Million Financing for Cancer Trials and Growth Initiatives Karyopharm Therapeutics has announced a strategic $100 million financing to expand operations and support growth, notably in myelofibrosis treatments.

Karyopharm Secures $100 Million Financing for Cancer Trials and Growth Initiatives #USA #Karyopharm #XPOVIO #Newton #Selinexor

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Karyopharm Completes Enrollment in Myelofibrosis Phase 3 SENTRY Trial: A New Dawn for Treatment Karyopharm Therapeutics has announced the completion of patient enrollment in the Phase 3 SENTRY trial for myelofibrosis, aiming to redefine treatment options.

Karyopharm Completes Enrollment in Myelofibrosis Phase 3 SENTRY Trial: A New Dawn for Treatment #United_States #Karyopharm #Newton #Myelofibrosis #Selinexor

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Karyopharm Therapeutics Unveils New Stock Grants Under Nasdaq Regulations Karyopharm Therapeutics Inc. reports new restricted stock grants for newly hired employees, enhancing its commitment to growth.

Karyopharm Therapeutics Unveils New Stock Grants Under Nasdaq Regulations #USA #Karyopharm #XPOVIO #Newton #KPTI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Karyopharm Therapeutics' Q2 2025 Financial Overview and Future Prospects Karyopharm Therapeutics has reported its financial results for Q2 2025, highlighting progress in clinical trials and revenue growth. The company anticipates significant developments ahead.

Karyopharm Therapeutics' Q2 2025 Financial Overview and Future Prospects #USA #Karyopharm #XPOVIO #Newton #Selinexor

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Karyopharm Therapeutics Grants Restricted Stock Units to New Employee under Nasdaq Rule 5635(c)(4) Karyopharm Therapeutics has granted restricted stock units to a new employee as part of its inducement plan, aligning with Nasdaq regulations.

Karyopharm Therapeutics Grants Restricted Stock Units to New Employee under Nasdaq Rule 5635(c)(4) #United_States #Karyopharm #XPOVIO #cancer_therapies #Newton,_Massachusetts

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Karyopharm Therapeutics Announces Restricted Stock Unit Grants Under Nasdaq Rule 5635(c)(4) Karyopharm Therapeutics has disclosed the grant of restricted stock units to new employees as an incentive under Nasdaq rules, showcasing their commitment to talent acquisition.

Karyopharm Therapeutics Announces Restricted Stock Unit Grants Under Nasdaq Rule 5635(c)(4) #United_States #NASDAQ #Karyopharm #RSUs #Newton

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Karyopharm Unveils Future Plans at Jefferies Global Healthcare Conference 2025 Karyopharm Therapeutics, a leader in innovative cancer therapies, will showcase its advancements at the Jefferies Global Healthcare Conference in New York.

Karyopharm Unveils Future Plans at Jefferies Global Healthcare Conference 2025 #United_States #New_York #Karyopharm #XPOVIO #cancer_therapies

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Karyopharm Therapeutics Unveils Inducement Grants to New Employees Under Nasdaq Regulations Karyopharm Therapeutics has announced the granting of restricted stock units as part of its employment strategy, reinforcing its commitment to innovative cancer therapies.

Karyopharm Therapeutics Unveils Inducement Grants to New Employees Under Nasdaq Regulations #NASDAQ #Karyopharm #XPOVIO

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Karyopharm Therapeutics to Showcase Innovations at 2025 Global Healthcare Conference Join Karyopharm Therapeutics as they highlight their advancements in cancer therapies at the RBC Capital Markets Global Healthcare Conference on May 21, 2025.

Karyopharm Therapeutics to Showcase Innovations at 2025 Global Healthcare Conference #USA #New_York #Karyopharm #XPOVIO #cancer_therapies

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Karyopharm's Selinexor Shows Promise for Myelofibrosis at EHA 2025 Karyopharm Therapeutics will present findings on selinexor, showcasing its effect on myelofibrosis patients at the 2025 EHA Meeting in Milan, indicating significant therapeutic potential.

Karyopharm's Selinexor Shows Promise for Myelofibrosis at EHA 2025 #United_States #Karyopharm #Newton #Myelofibrosis #Selinexor

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

Karyopharm's First Quarter 2025 Highlights Promising Developments in Myelofibrosis Research Karyopharm Therapeutics Inc. reports a solid first quarter of 2025, showcasing key advancements in the treatment of Myelofibrosis with Selinexor, highlighting revenue growth and clinical trial progress.

Karyopharm's First Quarter 2025 Highlights Promising Developments in Myelofibrosis Research #USA #Karyopharm #Newton #Myelofibrosis #Selinexor

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

Karyopharm Therapeutics Enhances Workforce with Inducement Grants to New Hires Karyopharm Therapeutics announced the granting of restricted stock units to new employees as part of their hiring initiative, following Nasdaq guidelines.

Karyopharm Therapeutics Enhances Workforce with Inducement Grants to New Hires #United_States #Karyopharm #XPOVIO #Newton #KPTI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Karyopharm Therapeutics Secures New Talent with Inducement Stock Awards Under Nasdaq Rule Karyopharm Therapeutics has issued 1,850 restricted stock units to new employees, enhancing its workforce to further advance cancer therapies. This follows Nasdaq Listing Rule regulations.

Karyopharm Therapeutics Secures New Talent with Inducement Stock Awards Under Nasdaq Rule #United_States #Karyopharm #XPOVIO #Newton #CancerTherapies

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Innovative XPOVIO Continues to Transform the Oncology Landscape with New Approvals and Market Growth XPOVIO, a groundbreaking oral cancer treatment, is reshaping the oncology market with new indications and impressive performance, aiming to meet the growing demand.

Innovative XPOVIO Continues to Transform the Oncology Landscape with New Approvals and Market Growth #United_States #Las_Vegas #oncology #Karyopharm #XPOVIO

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Karyopharm Therapeutics Announces Inducement Grants for New Employees Under Nasdaq Listing Rule Karyopharm Therapeutics Inc. has granted restricted stock units to new hires as part of their incentive plan. Learn more about this development.

Karyopharm Therapeutics Announces Inducement Grants for New Employees Under Nasdaq Listing Rule #USA #Karyopharm #XPOVIO #Newton #RSU_Grants

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Karyopharm Therapeutics Implements 1-for-15 Reverse Stock Split to Boost Share Value Karyopharm Therapeutics announces a 1-for-15 reverse stock split effective February 25, aiming to bolster its stock price for Nasdaq compliance.

Karyopharm Therapeutics Implements 1-for-15 Reverse Stock Split to Boost Share Value #USA #Karyopharm #XPOVIO #Newton #KPTI

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Karyopharm Reports Solid Financial Results for 2024 and Updates Clinical Trials for Cancer Treatments Karyopharm Therapeutics has released its financials for 2024, showing stable revenues and outlining updates on key cancer clinical trials, including selinexor's performance.

Karyopharm Reports Solid Financial Results for 2024 and Updates Clinical Trials for Cancer Treatments #USA #Karyopharm #XPOVIO #Newton,_Massachusetts #Selinexor

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Karyopharm Therapeutics Grants Stock Units to New Employees Following Nasdaq Listing Rules Karyopharm Therapeutics has awarded stock units to new hires under Nasdaq rules, showcasing its commitment to attracting talent in cancer therapy innovation.

Karyopharm Therapeutics Grants Stock Units to New Employees Following Nasdaq Listing Rules #United_States #Karyopharm #XPOVIO #Newton #CancerTherapy

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Karyopharm's 2024 Revenue Preview and 2025 Objectives Amid Myelofibrosis Research Progress Karyopharm Therapeutics reveals its preliminary revenue estimates for 2024 and outlines strategic objectives for 2025, focused on Myelofibrosis treatment.

Karyopharm's 2024 Revenue Preview and 2025 Objectives Amid Myelofibrosis Research Progress #USA #Karyopharm #Newton #Myelofibrosis #Selinexor